Subsequently, we performed a Fine-Gray regression model that included the age, sex, different tumor histology (adenocarcinoma vs. nonadenocarcinoma), tumor stage (localized stage vs. distant metastasis), Eastern Cooperative Oncology Group performance status (0–1 vs. 2–3), EGFR and KRAS mutations (mutated vs. wild-type) to identify the factors associated with VTE. This evidence concerns the gene KRAS and neoplasm.